


AMXI-5001

| | | | |
|--------------------|--|-------|----------|
| Cat. No.: | HY-145734 | | |
| CAS No.: | 2170491-77-5 | | |
| Molecular Formula: | C ₂₅ H ₂₀ FN ₅ O ₃ | | |
| Molecular Weight: | 457.46 | | |
| Target: | Microtubule/Tubulin | | |
| Pathway: | Cell Cycle/DNA Damage; Cytoskeleton | | |
| Storage: | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 6 months |
| | | -20°C | 1 month |



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (109.30 mM; ultrasonic and warming and heat to 60°C)

| Concentration | Solvent | Mass | | |
|---------------------------|---------|-----------|------------|------------|
| | | 1 mg | 5 mg | 10 mg |
| Preparing Stock Solutions | 1 mM | 2.1860 mL | 10.9299 mL | 21.8598 mL |
| | 5 mM | 0.4372 mL | 2.1860 mL | 4.3720 mL |
| | 10 mM | 0.2186 mL | 1.0930 mL | 2.1860 mL |

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

AMXI-5001 is a potent, orally active, and dual parp1/2 and microtubule polymerization inhibitor. MXI-5001 exhibits selective antitumor cytotoxicity across a wide variety of human cancer cells with much lower IC₅₀s than existing clinical PARP1/2 inhibitors. AMXI-5001 induces complete regression of established tumors, including exceedingly large tumors^[1].

REFERENCES

[1]. Lemjabbar-Alaoui H, et al. AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers. Am J Cancer Res. 2020;10(8):2649-2676.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA